CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

https://doi.org/10.5281/zenodo.15311012

Available online at: http://www.iajps.com *Research Article*

BACTERIAL GASTROENTERITIS-UPDATED DATA FOR HEALTHCARE PROFESSIONALS

[1]Mousa Saleh E Alhazmi, [2]Bassam Mohammed Tana Almutlaq, [3]Mohammed Mejdl Alruwaili, [4]Naif shaim Alanazi, [5]Sultan Fayadh Alanazi, [6]Basheer Sunaytan Aldahmashi

[1]Saudi Red Crescent Authority
[2]Saudi Red Crescent Authority
[3]Saudi Red Crescent Authority
[4]Emergency Medical Services Technician
[5]Saudi Red Crescent Authority
[6]Saudi Red Crescent Authority

Abstract:

Background: *Bacterial gastroenteritis is a major global health concern characterized by inflammation of the stomach and small intestine, leading to diarrhea, vomiting, and abdominal pain. It is caused by pathogens such as Salmonella, Campylobacter, and Shiga toxin-producing E. coli (STEC), with varying severity based on host factors and geographic location.*

Aim: *This article provides updated clinical data for healthcare professionals on the etiology, pathophysiology, diagnosis, and management of bacterial gastroenteritis, emphasizing evidence-based approaches to improve patient outcomes.*

Methods: *A comprehensive review of current literature was conducted, focusing on epidemiology, histopathology, diagnostic evaluation, and treatment protocols. Data from surveillance programs (e.g., CDC FoodNet) and clinical guidelines were analyzed.*

Results: *Bacterial gastroenteritis accounts for 48 million annual cases in the U.S., with Salmonella and Campylobacter being predominant. Severe cases often require hospitalization, especially in high-risk groups (e.g., elderly, immunocompromised). Diagnosis hinges on stool cultures, toxin assays, and electrolyte monitoring. Treatment prioritizes rehydration, with antibiotics reserved for invasive infections (e.g., azithromycin for Campylobacter). Complications like hemolytic uremic syndrome (HUS) and Guillain-Barré syndrome underscore the need for timely intervention.*

Conclusion: *Effective management requires an interprofessional approach, combining hydration therapy, judicious antibiotic use, and patient education. Public health measures and antimicrobial stewardship are critical to reducing morbidity.*

Keywords: *Bacterial gastroenteritis, diarrhea, Salmonella, Campylobacter, rehydration, antibiotic stewardship.*

Corresponding author:
Mousa Saleh E Alhazmi,
Saudi Red Crescent Authority

QR code

Please cite this article in press Mousa Saleh E Alhazmi et al., ***Bacterial Gastroenteritis-Updated Data For Healthcare Professionals.,****Indo Am. J. P. Sci, 2024; 11 (11).*

INTRODUCTION:

Gastroenteritis originates from the Greek words *gastron*, meaning "stomach," and *enteron*, meaning "small intestine," thus referring to inflammation of the stomach and small intestine [1]. Medically, it is defined as a diarrheal disease characterized by an increase in bowel movement frequency, which may be accompanied by vomiting, fever, and abdominal pain. The clinical definition of diarrhea includes three or more loose or watery stools within 24 hours or a stool output of at least 200 grams per day [1]. Gastroenteritis is classified based on symptom duration into acute, persistent, chronic, and recurrent forms. Acute gastroenteritis lasts 14 days or fewer and is commonly caused by viral, bacterial, or parasitic infections [1]. Persistent gastroenteritis extends beyond 14 days but resolves within 30 days and is often linked to untreated infections or malabsorption conditions [1]. Chronic gastroenteritis persists for more than 30 days and may indicate underlying gastrointestinal disorders such as inflammatory bowel disease or chronic infections [1]. Recurrent gastroenteritis involves repeated episodes of diarrhea after a symptom-free period of at least seven days, suggesting reinfection or predisposing factors like immune dysfunction [1]. These classifications help guide clinical assessment and treatment strategies, ensuring appropriate management based on the disease's duration and underlying cause.

ETIOLOGY:

Gastroenteritis has multiple etiological agents, including bacterial, viral, fungal, and parasitic pathogens; however, this discussion will focus on bacterial causes [2]. The prevalence of infectious diarrhea varies significantly based on geographical location, urban versus rural settings, and host factors such as immune status and comorbidities [2]. Despite this variability, viruses—including norovirus, rotavirus, and adenovirus—remain the most common cause of acute infectious diarrhea globally. This is supported by studies demonstrating that stool cultures yield positive bacterial results in fewer than 5% of cases [2]. Apart from norovirus, other significant pathogens causing watery diarrhea include Clostridium perfringens and enterotoxigenic Escherichia coli (ETEC) [2]. Bacterial pathogens, however, are more frequently associated with severe diarrheal illness compared to viral or parasitic infections. For instance, a study involving otherwise healthy adults with severe diarrhea—defined as four or more watery stools per day for at least three days—found that bacterial pathogens were responsible in 87% of cases [2].

In the United States, the most prevalent bacterial causes of severe gastroenteritis are nontyphoidal Salmonella and Campylobacter species [2]. Surveillance data from the Centers for Disease Control and Prevention (CDC) FoodNet program in 2016 estimated incidence rates per 100,000 individuals as follows: Salmonella (15.4), Campylobacter (11.8), Shigella (4.6), Shiga toxin-producing E. coli (2.8), Vibrio (0.45), Yersinia (0.42), and Listeria (0.26) [2]. These findings highlight the significant burden of bacterial gastroenteritis, particularly from Salmonella and Campylobacter, which collectively account for a substantial proportion of foodborne illnesses in the U.S. Understanding these epidemiological trends is crucial for guiding public health interventions, diagnostic approaches, and treatment strategies, particularly in cases of severe or prolonged diarrhea where bacterial etiology is more likely [2].

Epidemiology

Acute infectious diarrhea remains one of the most prevalent global health concerns, affecting populations even in developed nations such as the United States. Worldwide, it is a leading cause of morbidity and mortality, contributing to an estimated 1.5 to 2.5 million deaths annually [3]. Among children under five years of age, diarrheal diseases represent the second most common cause of death due to infectious agents, affecting between 3 to 5 billion children each year [3]. In the U.S., acute gastroenteritis accounts for over 350 million cases annually, with foodborne bacterial pathogens responsible for approximately 48 million of these cases [3]. This condition leads to 1.5 million primary care visits each year and results in nearly 200,000 hospitalizations for children under five [3]. While mortality rates are relatively low in developed nations, acute gastroenteritis still causes around 300 deaths per year in the U.S. [3]. Hospital admission rates for diarrheal illnesses are significantly lower in high-income countries, including the U.S., the United Kingdom, and Canada, compared to developing regions. However, traveler's diarrhea remains a major concern, affecting more than 50% of individuals traveling from developed to developing countries [3]. In the U.S., hospitalization rates for children under five stands at 9 per 1,000 cases annually, while the U.K. and Australia report slightly higher rates of 12 per 1,000 [3]. Additionally, the incidence of *Clostridium difficile* infections has been rising in both pediatric and adult populations, further complicating the epidemiological landscape of infectious diarrhea [3]. These statistics underscore the substantial burden of gastroenteritis across different

populations and highlight the need for effective prevention and treatment strategies worldwide.

Pathophysiology of Gastroenteritis

The pathophysiology of bacterial gastroenteritis involves complex interactions between pathogenic microorganisms and the host's intestinal environment. Diarrheal illness occurs through several mechanisms, including bacterial adherence, mucosal invasion, and toxin production. Understanding these pathogenic strategies is crucial for accurate diagnosis and effective management of the disease [4].

Impaired Fluid Absorption and Secretory Mechanisms

The small intestine plays a vital role in fluid absorption, and disruption of its function is a key factor in the development of diarrhea. When pathogenic bacteria colonize the gut, they interfere with normal absorptive processes, leading to an imbalance in fluid homeostasis. Certain bacterial toxins stimulate the intestinal lining to secrete rather than absorb fluids, resulting in loose or watery stools. For example, *Vibrio cholerae* produces cholera toxin, which activates adenylate cyclase in enterocytes, leading to excessive chloride secretion and water loss [4]. Similarly, enterotoxigenic *Escherichia coli* (ETEC) secretes heat-labile (LT) and heat-stable (ST) enterotoxins, both of which disrupt ion transport and promote secretory diarrhea [4].

Infective Dose and Virulence Factors

The inoculum size required to cause infection varies significantly among bacterial pathogens. Some organisms, such as *Shigella* and enterohemorrhagic *E. coli* (EHEC), are highly infectious, with as few as 10–100 bacteria sufficient to cause disease. In contrast, *V. cholerae* requires a much larger inoculum (10^5–10^6 bacteria) to establish infection [4]. These differences in infectivity depend on the pathogen's ability to survive gastric acid, compete with normal gut flora, and evade host immune defenses.

Bacterial Adherence and Colonization

Adherence to the intestinal mucosa is a critical step in the pathogenesis of many enteric bacteria. Pathogens employ specialized surface structures, such as adhesins and pili, to anchor themselves to host epithelial cells. *V. cholerae*, for instance, utilizes the toxin-coregulated pilus (TCP) and accessory colonization factors to attach to the brush border of small intestinal enterocytes [4]. ETEC produces colonization factor antigens (CFAs), which facilitate its attachment to the upper small intestine before toxin production begins. Without proper adherence, many pathogens would be unable to colonize the gut effectively or deliver their virulence factors [4].

Invasion and Cytotoxic Effects

Some bacteria, including *Shigella* and enteroinvasive *E. coli* (EIEC), invade intestinal epithelial cells, leading to cell destruction and inflammatory diarrhea. These pathogens penetrate the mucosal barrier, multiply within epithelial cells, and spread laterally, causing tissue damage and ulceration. The resulting inflammation leads to dysentery, characterized by bloody stools containing pus and mucus [4]. Additionally, cytotoxins produced by bacteria such as *Shigella dysenteriae* (Shiga toxin) and EHEC (Shiga-like toxin) damage endothelial cells, contributing to hemorrhagic colitis and, in severe cases, hemolytic uremic syndrome (HUS) [4].

Toxin-Mediated Diarrhea

Bacterial toxins play a central role in the pathogenesis of gastroenteritis. Enterotoxins, such as those produced by *V. cholerae* and ETEC, act directly on intestinal secretory mechanisms without causing significant mucosal damage. These toxins often target intracellular signaling pathways (e.g., cyclic AMP or cGMP), leading to sustained fluid secretion [4]. In contrast, cytotoxins, including those from *Clostridium difficile* (toxins A and B) and EHEC, induce cell death and inflammation, resulting in a more severe clinical presentation. The inflammatory response further exacerbates fluid loss and tissue damage, complicating disease progression [4]. The pathophysiology of bacterial gastroenteritis involves multiple mechanisms, including adherence, invasion, and toxin production, each contributing to the clinical manifestations of diarrhea. Understanding these processes aids in the identification of causative pathogens and guides appropriate therapeutic interventions. While some bacteria cause self-limiting watery diarrhea, others lead to severe inflammatory or bloody diarrhea, necessitating targeted treatment strategies [4].

Histopathology of Gastrointestinal Infections

The histopathological manifestations of gastrointestinal infections vary significantly depending on the causative pathogen, with distinct patterns of tissue response observable upon microscopic examination. These patterns can be broadly categorized into three groups based on their histological presentation [5]. First, some infections induce minimal or no discernible histologic changes, despite causing clinical symptoms. Vibrio species typically fall into this category, often showing nearly normal intestinal mucosa despite producing severe

watery diarrhea [5]. Second, many bacterial pathogens provoke nonspecific inflammatory changes. Campylobacter jejuni infections commonly demonstrate this pattern, featuring neutrophilic infiltrates, edema, and congestion without pathognomonic features [5]. The third and most diagnostically significant group comprises infections that produce characteristic histological features. These include pseudomembranous colitis caused by Clostridioides difficile, with its hallmark pseudomembranes consisting of necrotic epithelial cells, fibrin, and inflammatory cells adherent to the damaged mucosa [5]. Similarly, certain viral infections like cytomegalovirus demonstrate typical intranuclear inclusions. Notably, several enteric pathogens - including Shigella spp, Salmonella spp, Yersinia, and pathogenic E. coli strains - share remarkably similar histopathological features. These typically include mucosal thickening, intraepithelial neutrophil accumulation, and bacterial clusters adherent to the epithelial surface [5]. The lamina propria often shows marked inflammatory infiltrates, while neutrophils frequently aggregate in the intestinal lumen and crypt bases. This common histopathological appearance reflects similar pathogenic mechanisms among these organisms, particularly their ability to invade the intestinal epithelium and provoke acute inflammatory responses [5].

History and Physical Examination in Gastroenteritis

History Findings:

Patients with gastroenteritis typically present with a constellation of gastrointestinal symptoms. The most common complaints include nausea (often preceding other symptoms), diarrhea (which may range from watery stools to bloody diarrhea in cases of dysentery), vomiting, and abdominal cramping or pain [6]. The presence of fever is particularly noteworthy as it suggests infection with invasive organisms such as Salmonella, Shigella, or Campylobacter species [6]. A thorough history should include inquiry about:

- Duration and frequency of symptoms
- Characteristics of stool (watery, bloody, mucoid)
- Recent food intake or travel history
- Contact with ill individuals
- Medication use (particularly recent antibiotic exposure)
- Underlying medical conditions

Physical Examination Findings:

On abdominal examination, patients typically demonstrate a soft abdomen, though mild to moderate tenderness may be present on palpation. Voluntary guarding may be observed but true rigidity is uncommon [6]. The most critical aspect of the physical examination is assessment for signs of dehydration and systemic illness:

Key Physical Findings:

1. Hydration Status:
    - Dry mucous membranes (dry, cracked lips and oral mucosa)
    - Decreased skin turgor (slow return of pinched skin)
    - Sunken eyes or fontanelles in pediatric patients
2. Cardiovascular Assessment:
    - Tachycardia (compensatory response to volume depletion)
    - Hypotension (indicating severe volume loss)
    - Orthostatic blood pressure changes (suggesting >10% fluid loss)
3. Systemic Signs:
    - Fever (suggesting invasive pathogen)
    - Altered mental status (lethargy, confusion)
    - Oliguria or anuria

Red Flags Warranting Hospitalization [6]:

- Significant dehydration (dry mucous membranes, poor skin turgor)
- Hemodynamic instability (tachycardia, hypotension)
- Neurological changes (confusion, lethargy)
- Hematochezia or bloody diarrhea
- Age >65 years with comorbidities
- Immunocompromised status (HIV, diabetes, immunosuppressive therapy)
- Failure of outpatient management
- Recent hospitalization or antibiotic use (raising concern for C. difficile)
- Inability to maintain oral hydration

The physical examination serves not only to confirm the diagnosis but more importantly to assess disease severity and guide management decisions. Particular attention should be paid to vulnerable populations including infants, elderly patients, and immunocompromised individuals who may decompensate more rapidly [6].

Evaluation of Bacterial Gastroenteritis

The evaluation of suspected bacterial gastroenteritis begins with a comprehensive history and thorough physical examination. Clinicians should focus on obtaining detailed food and medical histories,

assessing symptom duration and frequency, evaluating current volume status, and identifying any red flags that may indicate severe illness or complications [7]. While many cases of acute bacterial gastroenteritis are self-limiting and do not require extensive diagnostic testing, certain clinical scenarios warrant further investigation. Initial laboratory evaluation should include a serum electrolyte panel in patients with severe volume depletion to identify potential electrolyte derangements, such as hyponatremia or hypokalemia, which may require correction [7]. A complete blood count (CBC), though nonspecific for determining bacterial etiology, can provide valuable prognostic information. Leukocytosis may suggest invasive bacterial infection (e.g., Salmonella or Shigella) or pseudomembranous colitis due to Clostridioides difficile, while thrombocytopenia could indicate the development of hemolytic-uremic syndrome (HUS), particularly in cases of Shiga toxin-producing Escherichia coli (STEC) infection [7]. Blood cultures should be obtained in patients with high fever or systemic symptoms to evaluate for bacteremia, which may occur with invasive pathogens such as Salmonella typhi or Campylobacter species [7].

Stool testing for bacterial pathogens is indicated in patients with severe illness (e.g., dehydration, severe abdominal pain, or need for hospitalization), high-risk host factors (e.g., pregnancy, age >70 years, immunocompromised state, or significant comorbidities), or signs of inflammatory diarrhea (e.g., bloody or mucoid stools, high fever) [7]. Routine stool cultures typically screen for Salmonella, Campylobacter, and Shigella species. However, if infection with less common pathogens (e.g., Vibrio, Yersinia, Aeromonas, or Listeria) is suspected, specific microbiological testing and culture requests should be made [7]. In cases of bloody diarrhea, additional testing for Shiga toxin and fecal leukocytes is essential to diagnose STEC infection, which carries a risk of HUS. For patients with persistent diarrhea (>14 days), stool samples should be sent for ova and parasite testing to evaluate for parasitic causes, particularly in travelers or immunocompromised individuals [7]. The judicious use of diagnostic testing ensures appropriate management while avoiding unnecessary interventions in mild, self-limiting cases. Clinicians must balance the need for etiological diagnosis with the clinical context, particularly in high-risk populations where targeted therapy may be warranted [7].

Treatment and Management of Bacterial Gastroenteritis

The management of bacterial gastroenteritis primarily focuses on supportive care, with antibiotic therapy reserved for specific cases. Most cases of noninflammatory diarrhea are self-limiting and resolve without antimicrobial treatment. However, appropriate clinical judgment is essential to identify patients who require more aggressive intervention [8].

Supportive Management

The cornerstone of treatment is **rehydration**, which should be initiated as soon as possible. **Oral rehydration solutions (ORS)** containing balanced electrolytes and glucose are preferred for mild to moderate dehydration, as they enhance intestinal fluid absorption. If oral rehydration is unsuccessful due to severe vomiting or altered mental status, **intravenous (IV) fluids** (e.g., normal saline or lactated Ringer's solution) should be administered. Monitoring for signs of volume depletion (e.g., tachycardia, hypotension, poor skin turgor) is critical, particularly in vulnerable populations such as young children, elderly patients, and immunocompromised individuals [8].

Antibiotic Therapy

Antibiotics are **not routinely recommended** for all bacterial gastroenteritis cases and may even be harmful in certain infections, such as **Shiga toxin-producing *E. coli* (STEC)**, where antibiotic use can increase the risk of hemolytic-uremic syndrome (HUS). However, empiric antibiotic therapy may be indicated in:

- **Severe illness** (>6 stools/day, high fever, hospitalization)
- **High-risk patients** (age >70, immunocompromised, significant comorbidities)
- **Suspected invasive infections** (bloody/mucoid stools, systemic symptoms)

First-line agents include:

- **Azithromycin or fluoroquinolones** (e.g., ciprofloxacin) for *Salmonella*, *Shigella*, and *Campylobacter* infections
- **Tetracyclines (e.g., doxycycline)** for *Vibrio cholerae*
- **Ampicillin** for *Listeria monocytogenes* in pregnant women

For **Clostridioides difficile infection (CDI)**, treatment depends on severity:

- **Non-severe CDI**: Oral vancomycin or fidaxomicin (preferred over metronidazole per CDC 2018 guidelines)
- **Severe/fulminant CDI**: Combination therapy with oral vancomycin **plus** IV metronidazole [8].

Symptomatic Therapy

Antimotility agents (e.g., loperamide) may be used cautiously in **afebrile patients with non-bloody diarrhea** to reduce stool frequency. However, they should be **avoided** in inflammatory diarrhea (e.g., *Shigella*, *C. difficile*) due to the risk of worsening toxin-mediated disease [8]. Management of bacterial gastroenteritis should be tailored based on clinical severity, host factors, and suspected pathogen. While most cases resolve rehydration alone, timely antibiotic therapy is crucial in high-risk or severely ill patients. Proper diagnosis and judicious use of antimicrobials optimize outcomes while minimizing complications [8].

Differential Diagnosis of Acute Bacterial Gastroenteritis

The clinical presentation of acute bacterial gastroenteritis overlaps with numerous other gastrointestinal disorders, necessitating careful consideration of alternative diagnoses. While bacterial pathogens (e.g., Salmonella, Campylobacter, Shigella, and diarrheagenic E. coli) are common culprits, viral (norovirus, rotavirus, adenovirus) and parasitic (Giardia, Cryptosporidium, Entamoeba histolytica) infections can produce similar symptoms of nausea, vomiting, diarrhea, and abdominal pain [9]. Foodborne illnesses, including toxin-mediated syndromes (e.g., Staphylococcus aureus or Bacillus cereus food poisoning), should also be considered, particularly in outbreaks with short incubation periods. Beyond infectious causes, inflammatory bowel diseases (Crohn's disease, ulcerative colitis) may mimic bacterial gastroenteritis, especially when presenting with bloody diarrhea or systemic symptoms. Pseudomembranous colitis due to Clostridioides difficile infection should be suspected in patients with recent antibiotic use or healthcare exposure. Less common but important considerations include microscopic colitis (lymphocytic or collagenous), which typically causes chronic watery diarrhea in older adults, and acute HIV infection, which can manifest with enteritis during seroconversion [9]. Functional disorders such as irritable bowel syndrome (IBS) and malabsorption conditions (lactose intolerance, celiac disease) may also present diarrhea but typically lack fever or signs of systemic illness. Medication-induced diarrhea (e.g., from antibiotics, laxatives, or magnesium-containing products) and endocrine disorders (hyperthyroidism, diabetic enteropathy) should be ruled out in persistent cases. A thorough history, including symptom duration, dietary habits, travel, and medication use, combined with targeted testing (stool studies, serology, or endoscopy when indicated), helps distinguish these entities [9].

Complications of Bacterial Gastroenteritis

The most frequent and clinically significant complication of acute bacterial gastroenteritis is dehydration, often accompanied by electrolyte imbalances (e.g., hyponatremia, hypokalemia, metabolic acidosis). These disturbances are particularly dangerous in vulnerable populations, including infants, elderly patients, and immunocompromised individuals, potentially leading to hemodynamic instability or renal failure if untreated [10]. Beyond acute fluid loss, gastroenteritis can trigger chronic gastrointestinal sequelae. Some patients develop post-infectious irritable bowel syndrome (PI-IBS) or secondary lactose intolerance due to transient lactase deficiency following enterocyte damage. Small intestinal bacterial overgrowth (SIBO) may also occur due to altered gut motility and microbiota disruption [10].

More severe systemic complications include:

- **Bacteremia/septicemia**: Especially with invasive pathogens like *Salmonella* (particularly in immunocompromised hosts) or *Campylobacter*
- **Enteric fever**: Caused by *Salmonella* Typhi/Paratyphi
- **Guillain-Barré syndrome (GBS)**: An autoimmune neuropathy strongly associated with prior *Campylobacter jejuni* infection (responsible for ~30% of GBS cases) [10]
- **Reactive arthritis (Reiter's syndrome)**: Typically occurs 1–4 weeks after infections with *Shigella*, *Salmonella*, *Campylobacter*, or *Yersinia*, often in HLA-B27-positive individuals
- **Hemolytic uremic syndrome (HUS)**: A life-threatening complication of Shiga toxin-producing *E. coli* (STEC) infections, characterized by acute kidney injury, thrombocytopenia, and microangiopathic hemolytic anemia

Immunocompromised patients may experience chronic or relapsing infections (e.g., Cryptosporidium in AIDS). Additionally, acute gastroenteritis can exacerbate underlying inflammatory bowel disease (IBD), mimicking an IBD flare [10]. Early recognition and management of these complications are essential to reduce morbidity and mortality.

Enhancing Healthcare Team Outcomes in Bacterial Gastroenteritis Management

Effective management of bacterial gastroenteritis requires a collaborative, interprofessional approach involving primary care physicians, nurse practitioners, emergency department providers, infectious disease specialists, pharmacists, and nursing staff. This team-based strategy ensures comprehensive patient care, from accurate diagnosis to appropriate treatment and follow-up [10][11][12].

Key Roles in Patient Management

1. **Primary Care Providers & Emergency Physicians**:
   - Perform initial clinical assessment, focusing on **hydration status** and identification of **red flags** (e.g., severe dehydration, bloody diarrhea, systemic symptoms).
   - Initiate **rehydration therapy** (oral or IV) and determine need for hospitalization.
2. **Nurse Practitioners & Nursing Staff**:
   - Monitor **vital signs, fluid intake/output**, and electrolyte balance.
   - Educate patients/families on **oral rehydration solutions (ORS), dietary modifications**, and signs of worsening illness.
3. **Infectious Disease Specialists**:
   - Guide **antibiotic selection** in severe or complicated cases (e.g., immunocompromised hosts, suspected *C. difficile*).
   - Advise on **infection control measures** in outbreaks or resistant pathogens.
4. **Pharmacists**:
   - Ensure appropriate **antibiotic use** (e.g., avoiding fluoroquinolones in STEC infections).
   - Recommend **antidiarrheals cautiously** (e.g., loperamide only in non-inflammatory diarrhea).
5. **Laboratory & Microbiology Teams**:
   - Provide rapid **stool culture, toxin assays**, or PCR testing to confirm etiology.
   - Alert clinicians to **drug-resistant pathogens** or public health concerns (e.g., *Salmonella* outbreaks).

Preventing Complications

- **Dehydration & Electrolyte Imbalances**: Early fluid resuscitation reduces renal failure risk.
- **Chronic Sequelae**: Monitor for post-infectious IBS, lactose intolerance, or reactive arthritis.
- **Systemic Complications**: Recognize Guillain-Barré syndrome (post-Campylobacter), HUS (STEC), or septicemia (in immunocompromised hosts) [10].

Improving Outcomes

- **Standardized Protocols**: Use evidence-based guidelines for rehydration and antibiotic stewardship.
- **Patient Education**: Emphasize hand hygiene, safe food practices, and when to seek care.
- **Follow-Up**: High-risk patients (elderly, infants, immunocompromised) require close monitoring.

With timely intervention and team coordination, most patients achieve excellent outcomes. Delayed care, however, increases risks of morbidity (e.g., chronic diarrhea, renal failure) and mortality, particularly in vulnerable populations [11][12] [13].

CONCLUSION:

Bacterial gastroenteritis remains a significant clinical and public health challenge, with its impact spanning from self-limiting cases to life-threatening complications. This review highlights the critical role of accurate diagnosis, emphasizing stool cultures and toxin testing to identify pathogens like *Salmonella*, *Campylobacter*, and STEC. The epidemiology reveals a disproportionate burden in vulnerable populations, including children under five and immunocompromised individuals, necessitating targeted interventions. The pathophysiology of bacterial gastroenteritis involves diverse mechanisms, including toxin production (*Vibrio cholerae*), mucosal invasion (*Shigella*), and inflammatory responses (*C. difficile*). Understanding these pathways aids in tailoring treatment, which primarily focuses on rehydration—oral for mild cases and intravenous for severe dehydration. Antibiotics, while beneficial for invasive infections (e.g., dysentery), must be avoided in STEC due to HUS risk. The 2018 CDC guidelines recommend oral vancomycin or fidaxomicin for *C. difficile*, reflecting evolving best practices. Complications such as HUS, reactive arthritis, and Guillain-Barré syndrome underscore the importance of early recognition and multidisciplinary care. An interprofessional team—including primary providers, nurses, pharmacists, and microbiologists—ensures optimal outcomes through coordinated hydration

management, antibiotic stewardship, and patient education. Preventive strategies, including food safety measures and hand hygiene, are paramount. For travelers, prophylactic measures can reduce diarrheal incidence. Future efforts should address antimicrobial resistance and vaccine development for pathogens like *Campylobacter*. In summary, bacterial gastroenteritis demands a balanced approach: rapid diagnosis, judicious treatment, and prevention. By integrating clinical expertise with public health initiatives, healthcare professionals can mitigate its global burden and improve patient care.

REFERENCES:

1. Hiyoshi H, Tiffany CR, Bronner DN, Bäumler AJ. Typhoidal Salmonella serovars: ecological opportunity and the evolution of a new pathovar. FEMS Microbiol Rev. 2018 Jul 01;42(4):527-541.
2. Kolsin JM, Lopman BA, Payne DC, Wikswo ME, Dunn JR, Halasa NB, Hall AJ. Evaluating Previous Antibiotic Use as a Risk Factor for Acute Gastroenteritis Among Children in Davidson County, Tennessee, 2014-2015. J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):e86-e91.
3. Dos Santos AMP, Ferrari RG, Conte-Junior CA. Virulence Factors in Salmonella Typhimurium: The Sagacity of a Bacterium. Curr Microbiol. 2019 Jun;76(6):762-773.
4. Huyen DTT, Hong DT, Trung NT, Hoa TTN, Oanh NK, Thang HV, Thao NTT, Hung DM, Iijima M, Fox K, Grabovac V, Heffelfinger J, Batmunkh N, Anh DD. Epidemiology of acute diarrhea caused by rotavirus in sentinel surveillance sites of Vietnam, 2012-2015. Vaccine. 2018 Dec 14;36(51):7894-7900.
5. Altaweel YA, Abdelaziz S, Fathy HA, AbdelBadea S. Correlative study between C-reactive protein, clinical severity, and nerve conduction studies in Guillain-Barrè syndrome. Egypt J Neurol Psychiatr Neurosurg. 2018;54(1):4.
6. Castaño-Rodríguez N, Underwood AP, Merif J, Riordan SM, Rawlinson WD, Mitchell HM, Kaakoush NO. Gut Microbiome Analysis Identifies Potential Etiological Factors in Acute Gastroenteritis. Infect Immun. 2018 Jul;86(7)
7. Yin Y, Zhou D. Organoid and Enteroid Modeling of *Salmonella* Infection. Front Cell Infect Microbiol. 2018;8:102.
8. Scallan E, Griffin PM, McLean HQ, Mahon BE. Hospitalisations due to bacterial gastroenteritis: A comparison of surveillance and hospital discharge data. Epidemiol Infect. 2018 Jun;146(8):954-960.
9. Kanamori H, Weber DJ, Gergen MF, DiBiase LM, Sickbert-Bennett EE, Rutala WA. Epidemiologic characteristics of health care-associated outbreaks and lessons learned from multiple outbreak investigations with a focus on the usefulness of routine molecular analysis. Am J Infect Control. 2018 Aug;46(8):893-898.
10. Menta PLR, Andrade MER, Leocádio PCL, Fraga JR, Dias MTS, Cara DC, Cardoso VN, Borges LF, Capettini LSA, Aguilar EC, Alvarez-Leite JI. Wheat gluten intake increases the severity of experimental colitis and bacterial translocation by weakening of the proteins of the junctional complex. Br J Nutr. 2019 Feb;121(4):361-373.
11. Mathew S, Smatti MK, Al Ansari K, Nasrallah GK, Al Thani AA, Yassine HM. Mixed Viral-Bacterial Infections and Their Effects on Gut Microbiota and Clinical Illnesses in Children. Sci Rep. 2019 Jan 29;9(1):865.
12. Shelke YP, Deotale VS, Maraskolhe DL. Spectrum of infections in acute febrile illness in central India. Indian J Med Microbiol. 2017 Oct-Dec;35(4):480-484.
13. Sattar, S. B. A., & Singh, S. (2023). Bacterial gastroenteritis. In *StatPearls [Internet]*. StatPearls Publishing.

الملخص: التهاب المعدة والأمعاء الجرثومي - بيانات محدثة لمقدمي الرعاية الصحية

الخلفية :يُعد التهاب المعدة والأمعاء الجرثومي مشكلة صحية عالمية رئيسية يتميز بالتهاب في المعدة والأمعاء الدقيقة، مما يؤدي إلى الإسهال والقيء وآلام البطن. تسببه مسببات الأمراض مثل السالمونيلا، العطيفة، والإشريكية القولونية المنتجة لسموم الشيغا(STEC) ، وتختلف شدته بناءً على عوامل المضاف والموقع الجغرافي.
الهدف :تقدم هذه المقالة بيانات سريرية محدثة لمقدمي الرعاية الصحية حول المسببات، الفيزيولوجيا المرضية، التشخيص، وإدارة التهاب المعدة والأمعاء الجرثومي، مع التركيز على النهج القائمة على الأدلة لتحسين نتائج المرضى.
الطرق :تم إجراء مراجعة شاملة للأدبيات الحالية، مع التركيز على علم الأوبئة، الأنسجة المرضية، التقييم التشخيصي، وبروتوكولات العلاج. تم تحليل البيانات من برامج المراقبة) مثل CDC FoodNet) والمبادئ التوجيهية السريرية.
النتائج :يسجل التهاب المعدة والأمعاء الجرثومي 48 مليون حالة سنويًا في الولايات المتحدة، مع هيمنة السالمونيلا والعطيفة. غالبًا ما تتطلب الحالات الشديدة دخول المستشفى، خاصة في الفئات عالية الخطورة (مثل كبار السن، ذوي المناعة الضعيفة). يعتمد التشخيص على مزرعة البراز، اختبارات السموم، ومراقبة الكهارل. يُعطي العلاج الأولوية لإعادة الترطيب، مع حفظ المضادات الحيوية للالتهابات الغازية (مثل أزيثروميسين للعطيفة). تُذكر مضاعفات مثل متلازمة انحلال الدم اليوريمية (HUS) ومتلازمة غيلان باريه بالحاجة إلى التدخل في الوقت المناسب.
الاستنتاج :تتطلب الإدارة الفعالة نهجًا متعدد التخصصات، يجمع بين علاج الترطيب، الاستخدام الحكيم للمضادات الحيوية، وتثقيف المرضى. تعد تدابير الصحة العامة والإشراف على المضادات الميكروبية أمرًا بالغ الأهمية للحد من الممراضة.
الكلمات المفتاحية :التهاب المعدة والأمعاء الجرثومي، الإسهال، السالمونيلا، العطيفة، إعادة الترطيب، الإشراف على المضادات الحيوية.